Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
September 25, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Friday, Oct. 4,...
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
September 05, 2019 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79,...
Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
September 03, 2019 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2019 18:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2019,...
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
August 19, 2019 17:48 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had received a Complete...
Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS)
August 08, 2019 15:27 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, was informed earlier today that an adverse...
Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
August 07, 2019 16:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2019 18:04 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2019, that...
Sarepta Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Corporate Developments on August 7, 2019
July 31, 2019 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2019 financial...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2019 18:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2019, that...